Back

Results from a phase 1 multiple ascending dose study demonstrating safety and selectivity of aldosterone synthase inhibitor CIN-107

28 August 2022 (15:15 - 16:00)
Organised by:
Congress Presentation Part of: Hypertension - Pharmacotherapy Pharmacotherapy ESC Professional Premium Access ESC Congress 2022

About the speaker

Photo
Doctor Mason Freeman

CinCor Pharma, Boston (United States of America)

7 More presentations in this session

Presentation thumbnail
Intensive reduction of high normal blood pressures: PRINT-TAHA9 randomized clinical trial
Associate Professor A. Attar (Shiraz, IR)
Abstract Slides
Presentation thumbnail
Differentiated approach to the treatment of uncomplicated hypertensive crisis
Doctor M. Sadulloeva (Tashkent, UZ)
Abstract Slides
Presentation thumbnail
Blockade of the renin-angiotensin system as a therapeutic target of NAFLD: results of an experimental model of hypercholesterolemia
Professor D. Bertolim Precoma (Campina Grande do Sul, BR)
Abstract Slides
Presentation thumbnail
Hydrochlorothiazide does not lead to phototoxic reactions and DNA damage in healthy volunteers the HCTox study
Doctor F. Goetzinger (Basel, CH)
Abstract Slides
Presentation thumbnail
Comparative effect of 3 different fix-combination antihypertensive treatments in fasting glucose, fasting insulin, OGTT and HbA1c levels, in prediabetic hypertensive patients
Doctor A. Liontos (Ioannina, GR)
Abstract Slides

Access the full session

Session thumbnail
Hypertension - Pharmacotherapy

The Event

Event poster

ESC Congress 2022

28 August 2022 15:15 CET
You may be interested in
thumbnail
Congress Session
Challenges in hypertension management
thumbnail
Webinar
Management of blood pressure: selected case-based advice
thumbnail
Congress Presentation
Add-on treatment with zilebesiran for inadequately controlled hypertension: KARDIA-2 RCT

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources